ATP Assays Market to Grow at CAGR of 7.78% through 2030F
Integration
with next-generation sequencing and omics technologies and increased focus on
point-of-care diagnostics is expected to drive the Global ATP Assays Market
growth in the forecast period, 2026-2030.
According
to TechSci Research report, “ATP Assays Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2020-2030F”,
the Global ATP Assays Market stood at USD
3.37 Billion in 2024 and is expected to reach USD 5.30 Billion by
2030 with a CAGR of 7.78% during the forecast period.
The
shift towards bioluminescence-based ATP assays is a key trend driving growth in
the global ATP assays market. This technology has gained significant popularity
due to its high sensitivity, speed, and simplicity, making it a preferred
choice for a wide range of applications. Bioluminescence-based assays operate
by detecting light emitted when ATP reacts with the enzyme luciferase, a
reaction that generates photons proportional to the amount of ATP present. This
light emission serves as a direct indicator of ATP levels, making it a powerful
tool for quantifying microbial contamination and cell viability. One of the
main advantages of bioluminescence-based ATP assays is their ability to detect
very low levels of ATP, which is essential for applications requiring high
sensitivity, such as microbial detection in food safety or environmental
monitoring. Traditional methods, like culturing, can take hours or even days to
yield results, whereas bioluminescence assays provide rapid, real-time
measurements, often delivering results in less than 30 minutes. This speed of
detection is crucial for industries where time is of the essence, such as in
clinical diagnostics or pharmaceutical production.
Bioluminescence
assays are less prone to interference from other cellular components, offering
greater specificity compared to other ATP detection methods. This makes them
highly reliable in complex samples, such as biological fluids or industrial
products, where contamination with other substances might otherwise skew
results. As industries across the food and beverage, pharmaceutical, and environmental
monitoring sectors increasingly recognize the advantages of
bioluminescence-based ATP assays, the technology is becoming a dominant force
in the market. Its versatility, combined with cost-effectiveness and ease of
use, positions it as a preferred solution for both routine testing and advanced
research.
A
notable trend in the ATP assays market is the integration of ATP assays with
next-generation sequencing (NGS) and other omics technologies. This convergence
allows researchers to gain deeper insights into cellular metabolism and
function. By coupling ATP assays with transcriptomics, proteomics, or
metabolomics, researchers can obtain a more comprehensive understanding of
cellular processes, especially in drug discovery and disease modeling. This
trend is driving innovations in the ATP assays market, as multi-omics
approaches become more common in research settings, providing a more holistic
view of biological systems.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on
"Global ATP Assays Market”
The
Global ATP Assays Market is segmented into type, application, end
use, regional distribution, and company
Based
on end-user segments, pharmaceutical and biotechnology companies are the
dominant force in the Global ATP Assays Market, driven by the significant role
ATP assays play in drug discovery, clinical research, and bioprocessing. These
assays are instrumental in evaluating cellular metabolism, monitoring cell
viability, and assessing the effects of drug candidates on cell health. This
ability to rapidly measure cellular responses is essential in optimizing the
drug development process, especially in fields like oncology, immunotherapy,
and other therapeutic areas where understanding cellular behavior is critical
for therapeutic success. ATP assays provide reliable, high-throughput testing,
enabling researchers to screen potential drug candidates more efficiently and
with greater accuracy. ATP assays are widely used in the quality control of
biologic and pharmaceutical products, ensuring that manufactured drugs meet
safety and efficacy standards. In the production of biologics, where
maintaining cell culture health is crucial for product yield and quality, ATP
assays are used to monitor cell viability and growth. This makes them an
indispensable tool for maintaining product consistency, integrity, and
compliance with Good Manufacturing Practice (GMP) regulations.
As
pharmaceutical and biotechnology companies continue to pivot toward precision
medicine and the development of biologic therapies, ATP assays are becoming
even more critical. These assays allow for real-time monitoring of cellular
responses to new treatments, supporting the development of highly targeted,
personalized therapies. As the need for more sophisticated, efficient, and
accurate drug development methods grows, ATP assays are poised to remain
central to these industries’ research and manufacturing processes.
Based
on region, Europe is the second dominant region in the Global ATP Assays
Market. This is due to the region's strong pharmaceutical, biotechnology, and
healthcare sectors, which extensively use ATP assays for research, development,
and quality control in drug manufacturing. European countries, particularly the
United Kingdom, Germany, and France, are at the forefront of adopting advanced
diagnostic technologies, including ATP assays, across various applications such
as microbiology, environmental monitoring, and clinical diagnostics. In Europe,
the increasing emphasis on personalized medicine and biologics has driven the
demand for ATP assays. Pharmaceutical and biotechnology companies in the region
utilize ATP assays in drug development, especially in oncology, immunotherapy,
and other therapeutic areas requiring precise cellular monitoring. The adoption
of ATP assays in clinical settings for infection control and contamination
monitoring in hospitals and diagnostics laboratories is further boosting market
growth.
Europe
has a well-established regulatory framework and healthcare infrastructure that
supports the integration of advanced diagnostic technologies. This regulatory
environment encourages innovation and adoption of novel diagnostic solutions,
such as ATP-based assays, within the healthcare system. The presence of leading
research institutions, academic centers, and contract research organizations
(CROs) in the region further contributes to the demand for ATP assays for
research and clinical applications.
Major
companies operating in Global ATP Assays Market are:
- Thermo Fisher Scientific Inc.
- Promega Corporation
- PerkinElmer Inc.
- Becton, Dickinson and Company
(BD)
- Lonza Group AG
- DH Life Sciences, LLC.
- Abcam Limited
- Quest Diagnostics Incorporated
- BIOMÉRIEUX S.A.
- 3M Company
Download Free Sample Report
Customers
can also request for 10% free customization on this report
“The
increased focus on point-of-care (POC) diagnostics is a significant trend in
the ATP assays market, driven by technological advancements and the demand for
faster, more efficient diagnostic tools in healthcare. POC testing allows for
rapid and reliable results in non-laboratory settings, making it an invaluable
tool for healthcare professionals and patients, particularly in emergency
situations or remote areas. ATP assays are becoming integral to POC diagnostics
because they provide quick and accurate results for detecting bacterial
contamination, an essential feature in clinical environments where
time-sensitive decisions are crucial. For instance, ATP assays are particularly
useful in diagnosing wound infections, urinary tract infections (UTIs), and
other bacterial infections where early detection is critical for effective
treatment. The ability to detect microbial contamination at the point of care,
without the need for complex laboratory equipment or lengthy incubation times,
allows healthcare providers to make timely decisions regarding patient care,
such as administering the appropriate antibiotics or initiating infection
control measures. This can significantly reduce the risks associated with
undiagnosed infections, improving patient outcomes and minimizing hospital
readmission rates.The growing trend towards personalized healthcare is also
contributing to the rise of POC diagnostics. As healthcare increasingly moves
towards individualized treatment plans, on-the-spot testing solutions, such as
ATP assays, enable tailored interventions based on immediate test results. This
is particularly important in emerging markets, where access to centralized
laboratories can be limited, and there is a need for affordable, accessible
diagnostic tools that can be used in local clinics or even in the home.,” said
Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“ATP Assays
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Type (Luminometric ATP Assays, Enzymatic ATP Assays,
Bioluminescence Resonance Energy Transfer (BRET) ATP Assays, Cell-based ATP
Assays, Others), By Application (Drug Discovery and Development, Clinical
Diagnostics, Environmental Testing, Food Safety and Quality Testing, Others),
By End Use (Pharmaceutical and Biotechnology Companies, Academic and Research
Institutes, Hospital and Diagnostics Laboratories), By Region, and Competition, 2020-2030F”, has
evaluated the future growth potential of Global ATP Assays Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global ATP Assays Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com